Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Asset Purchase
1.2.3 Collaborative R&D
1.2.4 Joint Venture
1.2.5 Licensing
1.2.6 Other
1.3 Market by Application
1.3.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Pharmaceutical Industry
1.3.3 Biotechnology
1.3.4 Medical Care
1.3.5 Education and Research
1.3.6 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Perspective (2018-2033)
2.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Growth Trends by Region
2.2.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Historic Market Size by Region (2018-2023)
2.2.3 Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Region (2024-2033)
2.3 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Dynamics
2.3.1 Cancer Monoclonal Antibody Partnering Terms and Agreements Industry Trends
2.3.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Drivers
2.3.3 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Challenges
2.3.4 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players by Revenue
3.1.1 Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players by Revenue (2018-2023)
3.1.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Players (2018-2023)
3.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue
3.4 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Concentration Ratio
3.4.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in 2022
3.5 Cancer Monoclonal Antibody Partnering Terms and Agreements Key Players Head office and Area Served
3.6 Key Players Cancer Monoclonal Antibody Partnering Terms and Agreements Product Solution and Service
3.7 Date of Enter into Cancer Monoclonal Antibody Partnering Terms and Agreements Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cancer Monoclonal Antibody Partnering Terms and Agreements Breakdown Data by Type
4.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Historic Market Size by Type (2018-2023)
4.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Type (2024-2033)
5 Cancer Monoclonal Antibody Partnering Terms and Agreements Breakdown Data by Application
5.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Historic Market Size by Application (2018-2023)
5.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2018-2033)
6.2 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2018-2023)
6.4 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2018-2033)
7.2 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2018-2023)
7.4 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2018-2033)
8.2 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2018-2023)
8.4 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2018-2033)
9.2 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2018-2023)
9.4 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2018-2033)
10.2 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2018-2023)
10.4 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 3SBio
11.1.1 3SBio Company Detail
11.1.2 3SBio Business Overview
11.1.3 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.1.4 3SBio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.1.5 3SBio Recent Development
11.2 4D Pharma
11.2.1 4D Pharma Company Detail
11.2.2 4D Pharma Business Overview
11.2.3 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.2.4 4D Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.2.5 4D Pharma Recent Development
11.3 Abbvie
11.3.1 Abbvie Company Detail
11.3.2 Abbvie Business Overview
11.3.3 Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.3.4 Abbvie Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.3.5 Abbvie Recent Development
11.4 Abzena
11.4.1 Abzena Company Detail
11.4.2 Abzena Business Overview
11.4.3 Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.4.4 Abzena Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.4.5 Abzena Recent Development
11.5 Adaptive Biotechnologies
11.5.1 Adaptive Biotechnologies Company Detail
11.5.2 Adaptive Biotechnologies Business Overview
11.5.3 Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.5.4 Adaptive Biotechnologies Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.5.5 Adaptive Biotechnologies Recent Development
11.6 Aeglea BioTherapeutics
11.6.1 Aeglea BioTherapeutics Company Detail
11.6.2 Aeglea BioTherapeutics Business Overview
11.6.3 Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.6.4 Aeglea BioTherapeutics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.6.5 Aeglea BioTherapeutics Recent Development
11.7 Agenus Bio
11.7.1 Agenus Bio Company Detail
11.7.2 Agenus Bio Business Overview
11.7.3 Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.7.4 Agenus Bio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.7.5 Agenus Bio Recent Development
11.8 Ascension
11.8.1 Ascension Company Detail
11.8.2 Ascension Business Overview
11.8.3 Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.8.4 Ascension Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.8.5 Ascension Recent Development
11.9 Ascentage Pharma
11.9.1 Ascentage Pharma Company Detail
11.9.2 Ascentage Pharma Business Overview
11.9.3 Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.9.4 Ascentage Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.9.5 Ascentage Pharma Recent Development
11.10 Aslan Pharma
11.10.1 Aslan Pharma Company Detail
11.10.2 Aslan Pharma Business Overview
11.10.3 Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.10.4 Aslan Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.10.5 Aslan Pharma Recent Development
11.11 Telix Pharmaceuticals
11.11.1 Telix Pharmaceuticals Company Detail
11.11.2 Telix Pharmaceuticals Business Overview
11.11.3 Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.11.4 Telix Pharmaceuticals Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.11.5 Telix Pharmaceuticals Recent Development
11.12 Basilea Pharmaceutica
11.12.1 Basilea Pharmaceutica Company Detail
11.12.2 Basilea Pharmaceutica Business Overview
11.12.3 Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.12.4 Basilea Pharmaceutica Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.12.5 Basilea Pharmaceutica Recent Development
11.13 Bavarian Nordic
11.13.1 Bavarian Nordic Company Detail
11.13.2 Bavarian Nordic Business Overview
11.13.3 Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.13.4 Bavarian Nordic Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.13.5 Bavarian Nordic Recent Development
11.14 Baxalta
11.14.1 Baxalta Company Detail
11.14.2 Baxalta Business Overview
11.14.3 Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.14.4 Baxalta Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.14.5 Baxalta Recent Development
11.15 Bayer
11.15.1 Bayer Company Detail
11.15.2 Bayer Business Overview
11.15.3 Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.15.4 Bayer Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.15.5 Bayer Recent Development
11.16 Cantargia
11.16.1 Cantargia Company Detail
11.16.2 Cantargia Business Overview
11.16.3 Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.16.4 Cantargia Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.16.5 Cantargia Recent Development
11.17 Apollomics
11.17.1 Apollomics Company Detail
11.17.2 Apollomics Business Overview
11.17.3 Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.17.4 Apollomics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.17.5 Apollomics Recent Development
11.18 Chiome Bioscience
11.18.1 Chiome Bioscience Company Detail
11.18.2 Chiome Bioscience Business Overview
11.18.3 Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.18.4 Chiome Bioscience Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.18.5 Chiome Bioscience Recent Development
11.19 Clovis Oncology
11.19.1 Clovis Oncology Company Detail
11.19.2 Clovis Oncology Business Overview
11.19.3 Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.19.4 Clovis Oncology Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.19.5 Clovis Oncology Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Asset Purchase
Table 3. Key Players of Collaborative R&D
Table 4. Key Players of Joint Venture
Table 5. Key Players of Licensing
Table 6. Key Players of Other
Table 7. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 8. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 9. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Region (2018-2023)
Table 11. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 12. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Region (2024-2033)
Table 13. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Trends
Table 14. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Drivers
Table 15. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Challenges
Table 16. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Restraints
Table 17. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Players (2018-2023)
Table 19. Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements as of 2022)
Table 20. Ranking of Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Companies by Revenue (US$ Million) in 2022
Table 21. Global 5 Largest Players Market Share by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (CR5 and HHI) & (2018-2023)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Cancer Monoclonal Antibody Partnering Terms and Agreements Product Solution and Service
Table 24. Date of Enter into Cancer Monoclonal Antibody Partnering Terms and Agreements Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Type (2018-2023)
Table 28. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 29. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Type (2024-2033)
Table 30. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Application (2018-2023)
Table 32. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 33. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Application (2024-2033)
Table 34. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 35. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2018-2023) & (US$ Million)
Table 36. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2024-2033) & (US$ Million)
Table 37. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 38. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2018-2023) & (US$ Million)
Table 39. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2024-2033) & (US$ Million)
Table 40. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 41. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2018-2023) & (US$ Million)
Table 42. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2024-2033) & (US$ Million)
Table 43. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2018-2023) & (US$ Million)
Table 45. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2024-2033) & (US$ Million)
Table 46. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 47. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2018-2023) & (US$ Million)
Table 48. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2024-2033) & (US$ Million)
Table 49. 3SBio Company Detail
Table 50. 3SBio Business Overview
Table 51. 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 52. 3SBio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 53. 3SBio Recent Development
Table 54. 4D Pharma Company Detail
Table 55. 4D Pharma Business Overview
Table 56. 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 57. 4D Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 58. 4D Pharma Recent Development
Table 59. Abbvie Company Detail
Table 60. Abbvie Business Overview
Table 61. Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 62. Abbvie Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 63. Abbvie Recent Development
Table 64. Abzena Company Detail
Table 65. Abzena Business Overview
Table 66. Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 67. Abzena Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 68. Abzena Recent Development
Table 69. Adaptive Biotechnologies Company Detail
Table 70. Adaptive Biotechnologies Business Overview
Table 71. Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 72. Adaptive Biotechnologies Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 73. Adaptive Biotechnologies Recent Development
Table 74. Aeglea BioTherapeutics Company Detail
Table 75. Aeglea BioTherapeutics Business Overview
Table 76. Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 77. Aeglea BioTherapeutics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 78. Aeglea BioTherapeutics Recent Development
Table 79. Agenus Bio Company Detail
Table 80. Agenus Bio Business Overview
Table 81. Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 82. Agenus Bio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 83. Agenus Bio Recent Development
Table 84. Ascension Company Detail
Table 85. Ascension Business Overview
Table 86. Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 87. Ascension Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 88. Ascension Recent Development
Table 89. Ascentage Pharma Company Detail
Table 90. Ascentage Pharma Business Overview
Table 91. Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 92. Ascentage Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 93. Ascentage Pharma Recent Development
Table 94. Aslan Pharma Company Detail
Table 95. Aslan Pharma Business Overview
Table 96. Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 97. Aslan Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 98. Aslan Pharma Recent Development
Table 99. Telix Pharmaceuticals Company Detail
Table 100. Telix Pharmaceuticals Business Overview
Table 101. Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 102. Telix Pharmaceuticals Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 103. Telix Pharmaceuticals Recent Development
Table 104. Basilea Pharmaceutica Company Detail
Table 105. Basilea Pharmaceutica Business Overview
Table 106. Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 107. Basilea Pharmaceutica Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 108. Basilea Pharmaceutica Recent Development
Table 109. Bavarian Nordic Company Detail
Table 110. Bavarian Nordic Business Overview
Table 111. Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 112. Bavarian Nordic Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 113. Bavarian Nordic Recent Development
Table 114. Baxalta Company Detail
Table 115. Baxalta Business Overview
Table 116. Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 117. Baxalta Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 118. Baxalta Recent Development
Table 119. Bayer Company Detail
Table 120. Bayer Business Overview
Table 121. Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 122. Bayer Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 123. Bayer Recent Development
Table 124. Cantargia Company Detail
Table 125. Cantargia Business Overview
Table 126. Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 127. Cantargia Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 128. Cantargia Recent Development
Table 129. Apollomics Company Detail
Table 130. Apollomics Business Overview
Table 131. Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 132. Apollomics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 133. Apollomics Recent Development
Table 134. Chiome Bioscience Company Detail
Table 135. Chiome Bioscience Business Overview
Table 136. Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 137. Chiome Bioscience Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 138. Chiome Bioscience Recent Development
Table 139. Clovis Oncology Company Detail
Table 140. Clovis Oncology Business Overview
Table 141. Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 142. Clovis Oncology Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 143. Clovis Oncology Recent Development
Table 144. Research Programs/Design for This Report
Table 145. Key Data Information from Secondary Sources
Table 146. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type: 2022 VS 2033
Figure 3. Asset Purchase Features
Figure 4. Collaborative R&D Features
Figure 5. Joint Venture Features
Figure 6. Licensing Features
Figure 7. Other Features
Figure 8. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 9. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application: 2022 VS 2033
Figure 10. Pharmaceutical Industry Case Studies
Figure 11. Biotechnology Case Studies
Figure 12. Medical Care Case Studies
Figure 13. Education and Research Case Studies
Figure 14. Other Case Studies
Figure 15. Cancer Monoclonal Antibody Partnering Terms and Agreements Report Years Considered
Figure 16. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 17. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 18. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Region: 2022 VS 2033
Figure 19. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Players in 2022
Figure 20. Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements as of 2022)
Figure 21. The Top 10 and 5 Players Market Share by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in 2022
Figure 22. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Country (2018-2033)
Figure 24. United States Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. Canada Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Country (2018-2033)
Figure 28. Germany Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. France Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. U.K. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Italy Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Russia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Nordic Countries Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Region (2018-2033)
Figure 36. China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Japan Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. South Korea Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Southeast Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. India Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Australia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Country (2018-2033)
Figure 44. Mexico Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Brazil Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Country (2018-2033)
Figure 48. Turkey Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 49. Saudi Arabia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 50. 3SBio Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 51. 4D Pharma Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 52. Abbvie Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 53. Abzena Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 54. Adaptive Biotechnologies Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 55. Aeglea BioTherapeutics Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 56. Agenus Bio Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 57. Ascension Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 58. Ascentage Pharma Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 59. Aslan Pharma Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 60. Telix Pharmaceuticals Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 61. Basilea Pharmaceutica Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 62. Bavarian Nordic Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 63. Baxalta Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 64. Bayer Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 65. Cantargia Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 66. Apollomics Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 67. Chiome Bioscience Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 68. Clovis Oncology Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed